

Advances in Stem Cell-Based Therapies for Neonatal Hypoxic-Ischemic Encephalopathy: A Comprehensive Review

An Li *, Zeyu Li

Yunnan University, Kunming, Yunnan 650500, China

* Corresponding author: An Li

Abstract: Neonatal hypoxic-ischemic encephalopathy (NHIE) remains a leading cause of neonatal morbidity and mortality, often resulting in long-term neurological impairments. This review explores the potential of stem cell therapy as an emerging treatment for NHIE, focusing on recent advances in human pluripotent stem cells (hPSCs) and mesenchymal stem cells (MSCs). These stem cells are particularly promising due to their immunomodulatory properties and ability to secrete bioactive factors that promote tissue repair and regeneration. Research suggests that stem cell therapy can facilitate neural repair through various mechanisms, including engraftment, differentiation into mature neural cells, secretion of paracrine factors, and stimulation of endogenous neurogenesis. Moreover, stem cells exhibit anti-apoptotic effects and reduce inflammation and oxidative stress in damaged brain tissues. However, challenges such as immunocompatibility, control of differentiation, and long-term safety remain significant barriers to clinical translation. This article also examines the potential of combining stem cell therapy with therapeutic hypothermia (TH), which is currently the standard of care for NHIE, to improve treatment outcomes. Emerging technologies, including gene editing and personalized medicine, offer promising prospects for the future of NHIE treatment. Despite the challenges, stem cell therapy holds substantial potential as a pivotal strategy for treating NHIE, contingent upon further research and clinical trials.

Keywords: Neonatal Hypoxic-ischemic Encephalopathy (NHIE); Stem Cells; Therapeutic Hypothermia (TH); Neurogenesis.

1. Introduction

Neonatal hypoxic-ischemic encephalopathy (NHIE) is a major cause of neonatal morbidity and mortality, often leading to long-term neurological impairments such as epilepsy, cerebral palsy, and developmental delays. This condition is primarily caused by a lack of oxygen and blood flow to the brain during the perinatal period, leading to irreversible brain injury. NHIE affects approximately 3% of term infants, with a mortality rate of up to 60% and significant long-term disabilities in 30% of survivors. Despite the current use of therapeutic hypothermia (TH) as the standard of care, this treatment has shown limited efficacy in improving long-term neurological outcomes, particularly in severe cases of NHIE.

Stem cell therapy has emerged as a promising alternative or adjunct to conventional treatments, offering a potential solution for repairing brain injury and improving recovery. Stem cells, particularly human pluripotent stem cells (hPSCs) and mesenchymal stem cells (MSCs), possess the ability to self-renew and differentiate into various specialized cell types, including neurons. These properties, along with their immunomodulatory effects and capacity to secrete bioactive factors, make stem cells a valuable tool in regenerative medicine. Stem cell-based therapies may offer several therapeutic mechanisms for NHIE, such as promoting neurogenesis, reducing apoptosis, mitigating inflammation, and enhancing tissue repair through paracrine signaling.

While stem cell therapies offer great promise, challenges remain, including issues related to immunocompatibility, precise control over stem cell differentiation, and long-term safety. Additionally, there is limited research exploring the combination of stem cell therapy with therapeutic

hypothermia, a widely used treatment for NHIE. This review aims to provide a comprehensive overview of the potential role of stem cell therapy in treating NHIE, highlighting current research findings, challenges, and future directions in the field.

The key contributions of this paper are displayed as follows:

1. Providing a comprehensive review of current research on stem cell therapies for NHIE, including their therapeutic mechanisms and potential benefits.
2. Exploring the challenges and limitations of stem cell therapies, such as immunocompatibility and control over differentiation.
3. Investigating the potential for combining stem cell therapy with therapeutic hypothermia to enhance treatment outcomes.
4. Discussing the emerging technologies, such as gene editing and personalized medicine, that could optimize stem cell-based therapies for NHIE.

2. Methods

The methods employed in this study are designed to comprehensively review the current state of stem cell-based therapies for neonatal hypoxic-ischemic encephalopathy (NHIE), with a particular focus on evaluating their potential mechanisms, therapeutic effects, and challenges. This review involves the synthesis of existing preclinical and clinical data, experimental results, and theoretical models surrounding stem cell applications in NHIE treatment. The following steps outline the key methods used for this review:

2.1. Literature Review and Data Collection

The primary methodology utilized in this study was an

extensive literature review. The following steps were taken to gather and analyze relevant data:

Search Strategy: A comprehensive search was conducted in databases such as PubMed, Google Scholar, and Scopus to identify peer-reviewed articles, clinical trials, and preclinical studies related to NHIE, stem cell therapies (human pluripotent stem cells [hPSCs], mesenchymal stem cells [MSCs], and other stem cell types), and their applications in neonatal brain injury. Keywords included “neonatal hypoxic-ischemic encephalopathy,” “stem cell therapy,” “neural repair,” “mesenchymal stem cells,” and “human pluripotent stem cells.”

Selection Criteria: Studies were selected based on the following inclusion criteria: [1] studies investigating stem cell therapy for NHIE, [2] studies discussing the potential mechanisms and therapeutic effects of stem cell treatments, [3] preclinical models, and [4] clinical trials or translational research. Studies that focused on non-neonatal brain injuries, animal models without NHIE, or therapies unrelated to stem cells were excluded.

Data Extraction: From the selected studies, data on experimental design, stem cell types used, therapeutic outcomes (including functional recovery, neurological improvement, and survival rates), and molecular mechanisms (such as neurogenesis, anti-apoptotic effects, and anti-inflammatory responses) were extracted.

2.2. Mechanistic Analysis of Stem Cell Therapy for NHIE

A significant portion of the study involved reviewing the proposed mechanisms by which stem cells exert therapeutic effects in the treatment of NHIE. These mechanisms were evaluated based on findings from preclinical and clinical studies:

Stem Cell Differentiation and Engraftment: The capacity of stem cells to differentiate into neural cell types and integrate into the injured brain tissue was analyzed. Studies that reported stem cell engraftment, differentiation into neurons or glial cells, and the restoration of neural circuits were closely examined.

Paracrine Effects and Secretome: An analysis was conducted on the paracrine effects of stem cells, particularly their secretion of bioactive molecules such as neurotrophic factors, angiogenic factors, and cytokines, and how these factors contribute to neuroprotection and tissue regeneration in NHIE models.

Neurogenesis and Neural Repair: The role of stem cells in stimulating endogenous neurogenesis and promoting the proliferation of neural stem cells was explored. Studies demonstrating the ability of stem cells to promote neurogenesis in response to hypoxic-ischemic injury were considered.

Reduction of Apoptosis and Inflammation: The anti-apoptotic effects of stem cell therapy, as well as its capacity to reduce inflammation and oxidative stress, were evaluated based on findings from both animal models and clinical trials.

Combination Therapy with Therapeutic Hypothermia: Given the interest in combining stem cell therapy with hypothermia, studies investigating the potential synergistic effects of these two approaches were analyzed. Specific focus was given to the timing, methods of administration, and outcomes of combination therapy.

2.3. Clinical Trials and Safety Evaluation

A comprehensive review of ongoing or completed clinical trials investigating stem cell-based therapies for NHIE was conducted. Data was obtained from clinical trial registries and publications to evaluate:

Study Design: Information regarding the design of clinical trials, including randomization, control groups, blinding, and patient demographics.

Stem Cell Types Used: The different stem cell sources (e.g., autologous vs. allogeneic) and types (e.g., mesenchymal stem cells, induced pluripotent stem cells) used in clinical trials were identified.

Routes of Administration: The methods used for stem cell delivery (e.g., intravenous injection, intrathecal injection, direct brain infusion) were examined to determine their impact on efficacy and safety.

Outcome Measures: The main outcome measures, including neurological development, survival rates, cognitive function, and motor skills, were assessed. Adverse effects, such as immune rejection or tumor formation, were also considered.

Long-term Follow-up: The duration of follow-up in clinical trials was evaluated to determine whether the improvements observed were sustained over time and whether any long-term side effects were reported.

2.4. Data Synthesis and Comparative Analysis

Data from preclinical studies and clinical trials were synthesized and compared to identify trends, therapeutic benefits, and limitations of stem cell therapies for NHIE. The synthesis involved the following:

Preclinical vs. Clinical Outcomes: A comparison of the outcomes of preclinical models (such as rodents and non-human primates) with clinical trial data was conducted to assess the translation of stem cell therapy from animal models to humans.

Therapeutic Efficacy: The efficacy of stem cell therapies was evaluated in terms of both functional recovery and molecular mechanisms. Improvements in neurological function, brain structure, and tissue integrity were compared across different studies.

Challenges and Gaps: The challenges reported in both preclinical and clinical studies, such as immunocompatibility, differentiation control, and the integration of stem cells into neural circuits, were identified and summarized.

3. Results and Discussion

3.1. Review of Stem Cell Therapy in NHIE Treatment

1) Preclinical Studies: Mechanisms of Action

A comprehensive review of the available preclinical studies reveals a variety of mechanisms through which stem cells contribute to neuroprotection and repair in neonatal hypoxic-ischemic encephalopathy (NHIE). The results from animal models consistently show that stem cell therapy, particularly involving mesenchymal stem cells (MSCs) and pluripotent stem cells, has the potential to promote recovery following brain injury caused by hypoxia and ischemia.

Stem Cell Engraftment and Differentiation: Preclinical studies on the differentiation capacity of stem cells into neural cell types show mixed results. While some studies report successful engraftment of stem cells and their differentiation

into neurons or glial cells (Hoang et al.[5]; Kim et al.[6]), others find minimal integration into the neural network, suggesting that stem cell differentiation may not be the primary factor driving the observed therapeutic effects (Lee et al.[7]; Li et al.[8]). Nevertheless, these studies highlight that stem cells may act more through their paracrine effects and the secretion of bioactive factors rather than direct differentiation into functional neural cells.

Paracrine Effects: A significant body of evidence supports the notion that stem cells exert therapeutic benefits primarily through their secretome. Studies consistently show that stem cells secrete a variety of neurotrophic factors, chemokines, and angiogenic factors (Mukai et al.[9]), which contribute to tissue repair, reduce apoptosis, and promote angiogenesis. These factors have been shown to stimulate endogenous neurogenesis, modulate the inflammatory response, and improve the brain's microenvironment following hypoxic-ischemic injury.

Neurogenesis and Neural Repair: Several studies indicate that stem cell therapy facilitates neurogenesis in neonatal models of HI injury. By stimulating the proliferation of neural stem cells and enhancing the differentiation of endogenous progenitor cells, stem cells promote neuronal repair and functional recovery in the damaged regions of the brain (Nakanishi[10]). This effect is particularly critical in neonates, as the developing brain retains a higher potential for neurogenesis compared to adult brains.

Anti-Apoptotic and Anti-Inflammatory Effects: Stem cells have been shown to exhibit significant anti-apoptotic effects in the context of NHIE. Administration of stem cells reduces apoptotic cell death in the injured brain and mitigates the extent of neural damage (Paridaen et al.[11]). Furthermore, stem cell therapy is associated with a reduction in pro-inflammatory cytokines, which plays a crucial role in limiting secondary injury and preserving neural integrity after hypoxic-ischemic damage (Serrenho et al.[12]).

2) Clinical Trials: Evidence of Efficacy and Safety

A growing body of clinical trials has sought to evaluate the safety and efficacy of stem cell therapies for NHIE. Although most trials are still in their early phases, preliminary results suggest that stem cell therapy holds promise for improving neurological outcomes in neonates affected by NHIE.

Safety of Stem Cell Therapy: The clinical data available from ongoing trials suggests that stem cell therapy is generally well-tolerated, with few serious adverse effects. In trials involving human umbilical cord blood (UCB)-derived stem cells and bone marrow-derived mesenchymal stem cells (BM-MSCs), patients have not shown significant signs of immune rejection, tumor formation, or other severe side effects (She et al.[13]; Thoresen et al.[14]). These results are promising, as immune rejection remains one of the most significant challenges in stem cell therapy, particularly when using allogeneic stem cells.

Functional Improvement: While the evidence for clinical efficacy remains preliminary, several clinical trials have shown that stem cell therapy can lead to improved neurological function in neonates with NHIE. For example, stem cell transplantation has been associated with improved motor skills, cognitive function, and overall survival in children with severe NHIE (Xia et al.[15]). However, these improvements are often modest, and further studies are required to determine the long-term impact of stem cell therapy.

3) Combination Therapy: Stem Cells and Hypothermia

Therapeutic hypothermia (TH) remains the standard of care for NHIE; however, its efficacy is limited, particularly in cases of severe injury. Given the potential benefits of stem cell therapy, several studies have begun to explore the combined use of hypothermia and stem cells as a treatment strategy for NHIE.

Synergistic Effects of Hypothermia and Stem Cells: Evidence from preclinical studies suggests that combining stem cell therapy with therapeutic hypothermia may offer synergistic benefits. Hypothermia has been shown to reduce glutamate toxicity, oxidative stress, and energy deficits in the brain, which are key pathological features of NHIE (Xu et al.[16]). When combined with stem cell therapy, these neuroprotective effects may enhance tissue repair and functional recovery. Furthermore, hypothermia may facilitate stem cell engraftment by reducing inflammation and oxidative damage at the site of injury, creating a more favorable environment for stem cell therapy (Zhang et al.[17]).

Clinical Trials on Combination Therapy: Although there is limited data on the combination of hypothermia and stem cell therapy in NHIE patients, preliminary results are encouraging. Trials that explore the combination of erythropoietin and stem cells, for example, show enhanced neuroprotective effects and improved clinical outcomes in neonates with severe NHIE (Zhang et al.[18]). These findings support the hypothesis that a multi-modal approach may be more effective in treating NHIE than either therapy alone.

3.2. Challenges and Limitations

Despite the promising results of stem cell therapy, several challenges remain:

Immunocompatibility and Ethical Concerns: Immunocompatibility remains a major obstacle, particularly when using allogeneic stem cells. The risk of immune rejection may limit the widespread clinical application of stem cell therapy. Additionally, ethical concerns surrounding the use of human pluripotent stem cells and genetic modifications remain contentious in many countries.

Control of Stem Cell Differentiation: Achieving precise control over stem cell differentiation into functional neural cells is a significant challenge. Despite advances in stem cell culture techniques, the efficiency of differentiation remains suboptimal, and the exact pathways through which stem cells contribute to neural repair need further clarification.

Long-term Efficacy and Safety: The long-term efficacy and safety of stem cell therapies for NHIE have yet to be fully established. Many studies report short-term improvements, but the long-term outcomes, such as cognitive and neurological development, are not yet clear. There is also the need for longitudinal studies to assess the potential risks, including tumorigenesis and adverse immune responses.

This review highlights the growing body of evidence supporting the use of stem cell-based therapies for the treatment of NHIE. Stem cells, particularly BM-MSCs and hPSCs, offer considerable potential for promoting neurogenesis, reducing inflammation, and repairing damaged neural tissue[13]. However, the efficacy of these therapies in humans, particularly in neonates with severe NHIE, remains an area of active research. While preclinical studies have demonstrated promising outcomes, clinical data are still limited, and many questions remain regarding the optimal stem cell source, administration route, and treatment regimen.

Moreover, the combination of stem cell therapy with existing treatments, such as hypothermia, offers a promising

direction for future research. By leveraging the neuroprotective effects of hypothermia and the regenerative potential of stem cells, it is possible that a more effective treatment for NHIE can be developed, addressing both the immediate and long-term consequences of the condition[16].

In conclusion, while stem cell therapy shows promise in the treatment of NHIE, further clinical trials, long-term follow-up studies, and mechanistic research are needed to fully understand its therapeutic potential and overcome the remaining challenges.

4. Conclusion and Future Work

Stem cell therapy represents a promising avenue for treating neonatal hypoxic-ischemic encephalopathy (NHIE), a condition that leads to severe neurological impairments and long-term disabilities in affected infants. This paper has reviewed the potential of stem cell-based therapies, particularly focusing on human pluripotent stem cells (hPSCs) and mesenchymal stem cells (MSCs), in repairing brain injuries caused by hypoxia and ischemia. These stem cells possess significant regenerative capabilities, including self-renewal, differentiation into neural cell types, and the secretion of bioactive factors that support tissue repair. Stem cell therapies can promote neurogenesis, reduce apoptosis, alleviate inflammation, and facilitate tissue regeneration through paracrine signaling, all of which contribute to functional recovery in preclinical models of NHIE.

However, despite the promising preclinical results, the clinical translation of stem cell therapies faces several challenges. The immunocompatibility of allogeneic stem cells remains a significant barrier, as does the precise control of stem cell differentiation into the desired neural phenotypes. Additionally, the long-term safety and efficacy of stem cell therapies are yet to be fully established, requiring further research into potential risks such as tumor formation, immune rejection, and other unforeseen complications. Another critical aspect is the combination of stem cell therapy with current standard treatments, such as therapeutic hypothermia (TH), which has shown limited efficacy, particularly in severe cases of NHIE. While hypothermia offers neuroprotective effects by reducing inflammation, oxidative stress, and excitotoxicity, its effectiveness is insufficient in improving long-term neurodevelopmental outcomes in many neonates with NHIE. Therefore, a combined approach of stem cell therapy and hypothermia could address multiple aspects of the injury, leading to improved clinical outcomes.

The future of NHIE treatment lies in overcoming these challenges through the integration of advanced stem cell technologies and other therapeutic modalities. Emerging technologies such as gene editing, three-dimensional bioprinting, and tissue engineering offer new tools to improve the precision and functionality of stem cell-based therapies. Furthermore, personalized medicine, based on the genetic makeup of individual patients, holds great promise for optimizing therapeutic outcomes by tailoring treatments to each neonate's unique needs.

References

[1] Enweronu-Laryea C, Martinello K A, Rose M, et al. Core temperature after birth in babies with neonatal encephalopathy in a sub-Saharan African hospital setting[J]. *The Journal of physiology*, 2019, 597(15): 4013-4024.

[2] Gonzales-Portillo G S, Reyes S, Aguirre D, et al. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy[J]. *Frontiers in neurology*, 2014, 5: 147.

[3] Grandvuillemin I, Garrigue P, Ramdani A, et al. Long-term recovery after endothelial colony-forming cells or human umbilical cord blood cells administration in a rat model of neonatal hypoxic-ischemic encephalopathy[J]. *Stem cells translational medicine*, 2017, 6(11): 1987-1996.

[4] Hattori T, Sato Y, Kondo T, et al. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats[J]. *Developmental neuroscience*, 2015, 37(2): 95-104.

[5] Hoang D M, Pham P T, Bach T Q, et al. Stem cell-based therapy for human diseases[J]. *Signal transduction and targeted therapy*, 2022, 7(1): 1-41.

[6] Kim E S, Ahn S Y, Im G H, et al. Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats[J]. *Pediatric research*, 2012, 72(3): 277-284.

[7] Lee J A, Kim B I, Jo C H, et al. Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model[J]. *Pediatric research*, 2010, 67(1): 42-46.

[8] Li F, Yin C, Ma Z, et al. PHD3 mediates denervation skeletal muscle atrophy through Nf-κB signal pathway[J]. *The FASEB Journal*, 2021, 35(4): e21444.

[9] Mukai T, Mori Y, Shimazu T, et al. Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model[J]. *Neuroscience*, 2017, 355: 175-187.

[10] Nakanishi K, Sato Y, Mizutani Y, et al. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats[J]. *Scientific Reports*, 2017, 7(1): 44111.

[11] Paridaen J T M L, Janson E, Utami K H, et al. The nucleolar GTP-binding proteins Gnl2 and nucleostemin are required for retinal neurogenesis in developing zebrafish[J]. *Developmental biology*, 2011, 355(2): 286-301.

[12] Serrenho I, Rosado M, Dinis A, et al. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy: a systematic review of preclinical studies[J]. *International Journal of Molecular Sciences*, 2021, 22(6): 3142.

[13] She H Q, Sun Y F, Chen L, et al. Current analysis of hypoxic-ischemic encephalopathy research issues and future treatment modalities[J]. *Frontiers in Neuroscience*, 2023, 17: 1136500.

[14] Thoresen M, Tooley J, Liu X, et al. Time is brain: starting therapeutic hypothermia within three hours after birth improves motor outcome in asphyxiated newborns[J]. *Neonatology*, 2013, 104(3): 228-233.

[15] Xia G, Hong X, Chen X, et al. Intracerebral transplantation of mesenchymal stem cells derived from human umbilical cord blood alleviates hypoxic ischemic brain injury in rat neonates [J]. 2010.

[16] Xu J, Feng Z, Wang X, et al. hUC-MSCs exert a neuroprotective effect via anti-apoptotic mechanisms in a neonatal HIE rat model[J]. *Cell Transplantation*, 2019, 28(12): 1552-1559.

[17] Zhang J, Yang C, Chen J, et al. Umbilical cord mesenchymal stem cells and umbilical cord blood mononuclear cells improve neonatal rat memory after hypoxia-ischemia[J]. *Behavioural brain research*, 2019, 362: 56-63.

[18] Zhang X, Zhang Q, Li W, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells on neonatal rat hypoxic-ischemic encephalopathy[J]. *Journal of Neuroscience Research*, 2014, 92(1): 35-45.